• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Potential Process Control Issues With Abatacept.阿巴西普潜在的工艺控制问题。
Contact Context. 2024;2024.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.阿达木单抗、依那西普、英夫利昔单抗、聚乙二醇化赛妥珠单抗、戈利木单抗、托珠单抗和阿巴西普用于治疗既往未使用改善病情抗风湿药物治疗且仅在传统改善病情抗风湿药物治疗失败后的类风湿关节炎:系统评价和经济学评估。
Health Technol Assess. 2016 Apr;20(35):1-610. doi: 10.3310/hta20350.
4
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
5
The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.阿巴西普、阿达木单抗、依那西普和托珠单抗治疗幼年特发性关节炎的临床有效性和成本效益:一项系统评价和经济学评估
Health Technol Assess. 2016 Apr;20(34):1-222. doi: 10.3310/hta20340.
6
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.生物制剂或托法替布用于初治类风湿关节炎患者:一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2017 May 8;5(5):CD012657. doi: 10.1002/14651858.CD012657.
7
Rituximab for rheumatoid arthritis.利妥昔单抗用于治疗类风湿关节炎。
Cochrane Database Syst Rev. 2015 Jan 20;1(1):CD007356. doi: 10.1002/14651858.CD007356.pub2.
8
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.阿达木单抗、依那西普和英夫利昔单抗治疗成人类风湿关节炎有效性的系统评价及其成本效益的经济学评估。
Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420.
9
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.依那西普和英夫利昔单抗治疗银屑病关节炎:系统评价与经济学评估
Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. doi: 10.3310/hta10310.
10
Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.甲氨蝶呤单药治疗以及甲氨蝶呤与传统和生物改善病情抗风湿药物联合治疗类风湿关节炎:一项网状荟萃分析。
Cochrane Database Syst Rev. 2016 Aug 29;2016(8):CD010227. doi: 10.1002/14651858.CD010227.pub2.

本文引用的文献

1
Nonparametric Subcluster Detection in Large Hyperspaces.大型超空间中的非参数子聚类检测
Contact Context. 2023;2023.
2
Variability in Content of Hydrocortisone Sodium Succinate.氢化可的松琥珀酸钠含量的变异性。
Contact Context. 2023;2023. doi: 10.6084/m9.figshare.23573532. Epub 2023 Jun 25.
3
Quality Variations in Thyrotropin Alfa.促甲状腺素α的质量差异
Contact Context. 2023;2023. doi: 10.6084/m9.figshare.23524530. Epub 2023 Jun 20.
4
Analysis of efficacy and safety of abatacept for rheumatoid arthritis: systematic review and meta-analysis.分析阿巴西普治疗类风湿关节炎的疗效和安全性:系统评价和荟萃分析。
Clin Exp Rheumatol. 2023 Sep;41(9):1882-1900. doi: 10.55563/clinexprheumatol/2xjg0d. Epub 2023 Mar 7.
5
Abatacept ameliorates both glandular and extraglandular involvements in patients with Sjögren's syndrome associated with rheumatoid arthritis: Findings from an open-label, multicentre, 1-year, prospective study: The ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjögren's Syndrome Endocrinopathy) and ROSE II trials.阿巴西普可改善与类风湿关节炎相关的干燥综合征患者的腺体和腺体外受累:来自开放标签、多中心、1 年、前瞻性研究的结果:ROSE(阿巴西普治疗类风湿关节炎以改善干燥综合征的内分泌病)和 ROSE II 试验。
Mod Rheumatol. 2023 Jan 3;33(1):160-168. doi: 10.1093/mr/roac011.
6
Principal component analysis: a review and recent developments.主成分分析:综述与最新进展
Philos Trans A Math Phys Eng Sci. 2016 Apr 13;374(2065):20150202. doi: 10.1098/rsta.2015.0202.

阿巴西普潜在的工艺控制问题。

Potential Process Control Issues With Abatacept.

作者信息

Isaacs James T, Almeter Philip J, Hunter Aaron N, Lyman Thomas A, Zapata Stephanie P, Henderson Bradley S, Larkin Seth A, Long Lindsey M, Bossle Megan N, Bhaktawara Smaran A, Warren Matthew F, Lozier Austin M, Melson Joshua D, Fraley Savannah R, Relucio Eunice Hazzel L, Felix Margaret A, Reynolds Jeffrey W, Naseman Ryan W, Platt Thomas L, Lodder Robert A

机构信息

Department of Pharmacy Services, University of Kentucky Healthcare, Lexington, KY 40536.

Pharmacy Practice & Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536.

出版信息

Contact Context. 2024;2024.

PMID:40851918
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12370286/
Abstract

Abatacept is a medication administered through intravenous infusion. It is supplied as a sterile, white, preservative-free, freeze-dried powder. Each vial of drug contains 250 mg abatacept, maltose, monobasic sodium phosphate, and sodium chloride for administration. Abatacept is a fusion protein consisting of the extracellular domain of CTLA-4 linked to the modified Fc portion of human immunoglobulin G1. It is produced using recombinant DNA technology. Abatacept is indicated for moderately to severely active rheumatoid arthritis in adults and polyarticular juvenile idiopathic arthritis in pediatric patients 6 years of age and older. It can be used as monotherapy or in combination with other disease-modifying antirheumatic drugs or methotrexate. Inter-lot variability was detected in a library of 132 vials spread across 34 lots of abatacept-maltose for injection by the University of Kentucky Drug Quality Task Force. A subcluster detection test was run on 13 vials that were shown to be an outlier group (r=0.9940, r=0.9551, r=0.9865, =0.02). Five of these vials individually appeared 4 or more standard deviations from the library cluster.

摘要

阿巴西普是一种通过静脉输注给药的药物。它以无菌、白色、无防腐剂的冻干粉末形式提供。每瓶药物含有250毫克阿巴西普、麦芽糖、磷酸二氢钠和用于给药的氯化钠。阿巴西普是一种融合蛋白,由与人类免疫球蛋白G1的修饰Fc部分相连的CTLA-4细胞外结构域组成。它采用重组DNA技术生产。阿巴西普适用于成人中度至重度活动性类风湿关节炎以及6岁及以上儿童患者的多关节型幼年特发性关节炎。它可以作为单一疗法使用,也可以与其他改善病情的抗风湿药物或甲氨蝶呤联合使用。肯塔基大学药物质量特别工作组在分布于34批注射用阿巴西普-麦芽糖的132个小瓶库中检测到批次间变异性。对13个小瓶进行了子聚类检测试验,这些小瓶被证明是一个异常值组(r = 0.9940,r = 0.9551,r = 0.9865,= 0.02)。其中5个小瓶各自显示出与库聚类相差4个或更多标准差。